Structural valve deterioration of bioprosthetic aortic valves: An underestimated complication.
retrospective_cohort · Level III
Where this comes from
- Record sourced from PubMed, PMID 30415900.
- Also identified by DOI 10.1016/j.jtcvs.2018.08.086.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Structural valve deterioration (SVD) remains a major bioprosthesis-related complication, as recently described for the Mitroflow valve (models LX and 12A) (LivaNova, London, United Kingdom). The real incidence of the SVD risk remains unclear, often due to methodologic pitfalls by systematically using the Kaplan-Meier estimator and/or the Cox model. In this report, we propose for the first time a precise statistical modeling of this issue. Five hundred sixty-one patients who underwent aortic valve replacement with the aortic Mitroflow valve between 2002 and 2007 were included. We used an illness-death model for interval-censored data. Median follow-up was 6.6 years; 103 cases of SVD were diagnosed. The 4-year and 7-year SVD cumulative incidences after the first anniversary of surgery were 15.2% (95% confidence interval, 11.9-19.1) and 31.0% (95% confidence interval, 25.8-37.2), respectively. Female gender, dyslipidemia, chronic obstructive pulmonary disease, and severe patient-prosthesis mismatch were significant risk factors of SVD. The occurrence of SVD was associated with a 2-fold increase in the risk of death. Appropriate statistical models should be used to avoid underestimating the SVD complication associated with worse long-term survival.
Medical subject headings
- Aortic Valve
- Aortic Valve Stenosis
- Bioprosthesis
- Heart Valve Prosthesis
- Heart Valve Prosthesis Implantation
- Prosthesis Failure